Immunovia AB (publ)

Immunovia's capital structure is characterized by a low debt-to-equity ratio of 0.2, indicating a conservative leverage profile. The company holds substantial cash and equivalents of 51.18 million SEK, which is significantly higher than its total liabilities of 27.33 million SEK, resulting in a current ratio of 2.03. This liquidity position supports operational flexibility but does not currently include long-term debt obligations. Profitability metrics show a challenging performance, with a return on equity of -6.74% and a return on assets of -4.15%. These figures are well below the typical thresholds for sustainable performance in the healthcare equipment and technology industry, where positive returns are generally expected to justify R&D and commercialization investments. The company's revenue is concentrated in a single business segment focused on diagnostic solutions, with no disclosed geographic diversification. This lack of segment or geographic diversification increases exposure to market-specific risks, particularly in the early-stage diagnostic testing market. Growth trajectory is constrained, with a reported revenue of 156 million SEK and a significant operating loss of 24.16 million SEK. Analysts project a modest revenue increase to 4 million SEK, but this is inconsistent with the company's current revenue scale and does not reflect meaningful growth. The negative operating cash flow of 24.42 million SEK further limits reinvestment capacity. Risk factors include a low liquidity risk and low dilution potential, with no immediate filing-based flags detected. However, the company's negative net income and operating cash flow suggest ongoing financial stress. The absence of capital expenditures and the lack of a clear path to profitability raise concerns about long-term sustainability. Recent events include a consistent EPS estimate of -0.10 SEK, with the last actual EPS at -0.32 SEK, indicating a widening loss per share. The uniformity of analyst price targets at 0.48 SEK suggests limited upside potential in the near term, with no divergence in expectations.